Safety and Efficacy of APD356 in the Treatment of Obesity
Study Details
Study Description
Brief Summary
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Detailed Description
This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 28 days, to uncomplicated obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.
Study Design
Outcome Measures
Primary Outcome Measures
- Change in body weight []
Secondary Outcome Measures
- Safety []
- Changes in waist circumference, hip circumference and waist/hip ratio []
Eligibility Criteria
Criteria
-
Healthy male or nonpregnant, nonlactating females aged between 18 and 65 years (inclusive)
-
Body Mass Index (BMI) of 30-45 Kg/m^2.
-
Non-smoker
-
No concomitant medications
-
No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Pennington Biomedical Research Center | Baton Rouge | Louisiana | United States | 70808 |
Sponsors and Collaborators
- Eisai Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
- obesity information
- N. American Association for the Study of Obesity web page
- sponsor company web page
- Pennington Biomedical Research Center home web page
Publications
None provided.- APD356-003